Global Business News
/DISREGARD RELEASE: IASO Bio/
We are advised by IASO Bio that journalists and other readers should disregard the news release, IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics, issued 13-Aug-2026 over PR Newswire, as the release contained erroneous information.
以上新聞投稿內容由 PR Newswire 美通社 全權自負責任，若有涉及任何違反法令、違反本網站會員條款、有侵害第三人權益之虞，將一概由 PR Newswire 美通社 承擔法律及損害賠償之責任，與台灣產經新聞網無關。
